ISI

ISI upgraded its rating on Best Buy (NYSE: BBY) from Sell to Hold. In today's trading, BBY added 1.25% to its value to finish the day at $24.25.

ISI initiated its coverage of Carizzo Oil & Gas (NASDAQ: CRZO) with a 1 Rating and a price target of $47. On Tuesday, CRZO closed the day at $36.76.

ISI modified its price target on Celgene (NASDAQ: CELG) to $67. At the same time, the rating agency left its price target on United Therapeutics (NASDAQ: UTHR) unchanged at $65. On Friday, Celgene lost 1.1% of its value to finish the week at $59.30, while UTHR rose 1.07% to end the day at $57.38.

ISI provided color on Gilead Sciences (NASDAQ: GILD). In a research report published today, the rating agency commented on the company's HIV drug. In the report, ISI states, “What's interesting to us is that number of patients on GILD HIV drugs in the EU hasn't really grown. This is despite...

ISI provided color on United Stationers (NASDAQ: USTR). In a research report published today, ISI commented on the company's Q2 results. In the report, ISI states, “United Stationers reported adjusted 2Q EPS of $0.59, above our $0.56e, but below consensus estimates of $0.61. Lower sales and a...

ISI reiterated its Hold rating on SunTrust Banks (NYSE: STI). At the moment, the rating agency has a price target of $25 placed on the company's stock. On Thursday, STI closed the day at $25.71. Its shares added 1.05% to their value in today's pre-market trading to stand around $26.

ISI provided color on Human Genome Sciences (NASDAQ: HGSI). In a research report published today, ISI stressed some new fey facts about the company. In the report, ISI states, “1. Net pricing of $21k ($32k list price) in Germany (will launch later this week) [we think this price is generally in-...

ISI provided color on Bristol Myers Squibb (NYSE: BMY). In a research report published today, ISI commented on the likelihood FDA will not approve the company's new drug. In the report, ISI states, “We are lowering our probability of success for dapa from 55% to 20% to reflect the 9 to 6 negative...

ISI provided color on Novartis (NASDAQ: NVS). In a research report published today, ISI commented on the company's relation to Biogen Idec (NASDAQ: BIIB). In the report, ISI states,” A few tidbits from the slides related to Biogen: 1. Total patients on Gilenya have doubled from 6,500 in 1Q to...

In a research report published today, ISI summed up the results of 96 and 48 week IAS abstracts. In the report, ISI states, “1. The virologic failure rate used for the resistance analysis jumped from 9% to 14% in the Edurant arm and increased from 4.8% to 7.6% in the Sustiva arm. Thus, the...

ISI provided color on Biogen Idec (NASDAQ: BIIB). In a research report published today, ISI commented on the company's product Tysabri. In the report, ISI states, “Earlier today, BIIB released their July 2011 Tysabri update on the number of cases of PML for patients. Interestingly, they noted that...

ISI provided color on Biogen Idec (NASDAQ: BIIB). In a research report published today, ISI is optimistic about the company's new drug, which has the potential of outperforming its competitors. In the report, ISI states, “Abstracts for the ISTH meeting are out. For BIIB, the most important is the...

ISI reiterated its Buy rating on Nike (NYSE: NKE). At the same time, ISI raised its price target on the company's stock from $100 to $110. In today's trading, Nike added 0.2% to its value to trade around $89.96.

ISI reiterated its Buy rating on Bed Bath & Beyond (NASDAQ: BBBY). At the same time, ISI raised its price target on the company's stock from $60 to $61. In the report, ISI states, "Bed Bath & Beyond remains one of the few large cap growth names in hardlines, but at 13.2x our 2012e,...

ISI is out with its report today on Vornado Realty (NYSE: VNO), raising its PT from $91 to $93. In a note to clients, ISI writes, "Based on our $93 price target, we expect VNO to post a forward 12 month total return of +1%, compared to a +6% expectation for the REIT sector. VNO trades at a 5.8%...